VFA
TBPH icon

Virtus Fund Advisers’s Theravance Biopharma TBPH Stock Holding History

Virtus Fund Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$974K Buy
+34,929
New +$1.03M 0.01% 294
2014
Q3 		– Sell
-2,007
Closed -$64K – 1854
2014
Q2 		$64K Buy
+2,007
New +$60.4K ﹤0.01% 1700

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtus Fund Advisers's TBPH Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Theravance Biopharma (TBPH) in Q4 2017: 34,929 shares worth $974K. The stake represents 0.01% of the portfolio and ranks #294 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in TBPH as recently as Q2 2014.

Virtus Fund Advisers first reported a position in TBPH in Q2 2014 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold TBPH as of Q4 2017.

  • Virtus Fund Advisers held 34,929 shares of Theravance Biopharma worth $974K as of Q4 2017.
  • Theravance Biopharma was a new Virtus Fund Advisers position in Q4 2017.
  • Theravance Biopharma made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #294 holding.
  • Virtus Fund Advisers first reported a position in Theravance Biopharma in Q2 2014 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.